Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Oncolytics Biotech Inc. (USA)
ONCY | US
1.03
USD-0.06
-5.50%
ONCY | US
Loading StockChartView...
About Oncolytics Biotech Inc. (USA)
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
1.03
Open
1.12
High
1.12
Low
1.00
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessONCY | US
Risk
105.5
Sharpe
0.76
Luna's Score
39/100
Recommendation
Sell
Luna says (ONCY | US)
What's Working
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
107.6%1 month
105.5%3 months
100.6%6 months
91.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.80
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.79
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.45M
MarketCap
79.16M
MarketCap(USD)
79.16M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-138.22
Short ratio
5.43
Short perc.
1.41
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.26
Range1M
0.40
Range3M
0.51
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.96
Price X volume
946.31K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.60 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 79.16M | 3.66B | Emerging |
